EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
+0.0639 (+4.33%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.4761
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4800 - 1.5400
52 Week Range1.3800 - 4.5000
Avg. Volume238,085
Market Cap219.395M
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability

    OTCQX: EMHTF) has provided preliminary, unaudited financial results for the second quarter of 2019 for its BC-based 50%-owned joint venture, Pure Sunfarms (PSF). The Company will report its complete financial results for the second quarter ended June 30, 2019, after market close on Wednesday, August 28th, 2019, and host its second quarter 2019 financial results conference call on Thursday, August 29th, 2019 at 10:30 a.m. ET.

  • InvestorPlace

    10 Medical Marijuana Stocks to Cure Your Portfolio

    Editor's note: This story was previously published in April 2019. It has since been updated and republished.Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from its botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks Under $7 to Invest in Now Of course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away. * 7 Biometric Stocks to Watch as AI Rises However, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives?More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell.As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: AbbVie (ABBV)Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline. We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Source: Shutterstock Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Not that I would know, but growing cannabis allegedly isn't rocket science. With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Source: Shutterstock Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * 8 Dividend Aristocrat Stocks to Buy Now No Matter What It's important to be careful with pot stocks, though. On a year-to-date basis, EMHTF stock is down nearly 40%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is its management team. In my view, they're making smart decisions through their acquisitive strategy.Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. Since the January opener, shares have skyrocketed roughly 70% before plummeting but still has added 24% this year. The inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Source: Shutterstock Prior to its earnings report for the second quarter, I worried about the company's revenue target.Hit or exceed it, and management can stave off criticism, but speculators looking for a discounted price may want to put CRON stock back on their radar. Since the beginning of March, Cronos has shed more than 28%. However, the magnitude of volatility has declined noticeably in the past few days. * 5 Cheap Stocks to Buy Now That the Fed Cut Rates Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)In business, even the green kind, you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry.Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical cannabis products in that country.It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand.Despite momentum toward legalization, several financial institutions shy away from cannabis ventures.Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 10 Stocks to Buy on the Trade War Dip Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up 123% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category.So far this year, TRTC stock is down around 35%.And the bad news doesn't end there. Unlike many other marijuana stocks, Terra Tech has had trouble generating top-line growth.In its most recent earnings report for the second quarter, 2019 the company reported $10.37 million in sales. After two consecutive down quarters, this could signal that TRTC is redeemable.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock has jumped 78% since the beginning of this year.Source: Shutterstock From the opening price of April, Charlotte's Web shares gained a ridiculous 16%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity.Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 10 Cyclical Stocks to Buy (or Sell) Now Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana.Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network.However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure for CBIS stock. However, shares trade for less than .03 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPRF)On a surface level, GW Pharmaceuticals (OTCMKTS:GWPRF) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility.Source: Shutterstock Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases.That's the good news. The not-so-pleasant side of the coin, though, is market performance. While no one mistakes cannabis stocks as stable investment platforms, GWPRF stock is rough for even hardened botanical veterans.In December of last year, shares fell off a cliff before rebounding back toward low-earth orbit. Since then, it has added 69% so it's a really volatile stock. * 7 A-Rated Stocks Under $10 So is GWPRF stock worth a look now? Although I like how the company has stabilized, I don't care for its low volume. But GW Pharmaceuticals is a penny stock with underappreciated talents. If you have the nerve and the patience, it's worth your consideration.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.

  • 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk

    7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk

    [Editor's note: This story will be updated each week with new stocks and analysis. Please check back often for Mark's latest take on marijuana penny stocks.]Every investor has dreams of investing a couple thousand dollars into the penny stock company that with become the next Amazon (NASDAQ:AMZN) or Microsoft (NASDAQ:MSFT). Marijuana penny stocks are especially appealing to some of these investors because they understand how much potential this industry has.But you need to be very careful investing in this highly risky sector of the market. Many of these companies will not survive. There is a reason why they are trading as penny stocks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsA few weeks ago I was at the local farmers market and I had an interesting conversation with a farmer. I mentioned that I thought the vegetables that come from the market are significantly better than those that come from the grocery store. He said it was because the vegetables were grown with natural sunlight, while the ones grown in the grocery store were grown indoors or in greenhouses.That made me think about if the same thing applies to growing cannabis. I have done some research, and sure enough there is a trend towards outdoor growing. Investors are starting to understand that in many cases, the cost and quality advantages of growing outside exceed any advantages that can be gained by indoor or greenhouse growing. * 7 Stocks Under $7 to Invest in Now A few of the companies that I have included are in the cannabis outside growing (aka farming) business. In addition, I have also included a few stocks with cool technical patterns.These are not buy recommendations. I just want to give you some insight that may help your investments. Marijuana Penny Stocks: 48North Cannabis (NRTH)48North Cannabis (TSE:NRTH) produces and sells medical cannabis. This a company that I am looking at as a potential investment into outdoor growing. It recently announced that it completed planting its 100-acre outdoor growing facility.Most of the larger growers such as Tilray (NASDAQ:TLRY), Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) primarily grow their cannabis either in indoor growing facilities or greenhouses.As mentioned above, there are some advantages to indoor growing. These include things such as better security and the ability to grow yearlong in cold climates. However, some investors are starting to understand that the cost benefits of outdoor growing exceed any benefits that are derived from the other methods.In addition, similar to what the farmer told me, some marijuana consumers believe that cannabis that is grown under natural sunlight is better than that grown inside. If the big companies that are growing indoors do not address this dynamic, it could provide a great opportunity for companies like 48North. Emerald Health Therapeutics (EMHTF)Emerald Health Therapeutics (OTCMKTS:EMHTF) is a Canadian producer of cannabis products.Like 48North, the management of this company is putting some focus on outside growing. It recently announced that it had received it's outdoor cultivation license from Health Canada. The larger Canadian indoor growers have used their influence to slow down the issuance of outdoor licenses. However, as the industry is evolving, they are losing their ability to continue to do so.There are two other things happening here that may be bullish for EMHTF stock. First, it is holding above support around the $1.50 level. This level was where the lows were in December. * 8 Dividend Aristocrat Stocks to Buy Now No Matter What In addition, the company announced the appointment of a new CEO. Riaz Bandali has over 25 years of experience. The appointment of this veteran to run the company could give it an advantage over its competitors that are being managed by those with less experience. KushCo Holdings (KSHB)KushCo Holdings (OTCMKTS:KSHB) produces and sells packaging products for companies that are in the marijuana industry.KSHB stock is approaching the $4.30 level. In June and July, it found support there and sub sequentially rallied. At the end of July, the stock was oversold. If it gets to $4.30 again while being oversold, there is a chance it will rally again.When stocks get to important support levels and become oversold, they tend to rally. If they get to important support and spend time consolidating, they tend to eventually break the level and go lower.What does oversold mean? It is a measurement of momentum. It is where the price is today versus where it was X many days ago. When this number reaches an extreme on the downside, it is considered oversold.For example, statistics tell us the 95% of all trading should be within two standard deviations of the mean. If a stock is more than two standard deviations below the mean, it would be considered oversold. Cannabis Sativa (CBDS)Cannabis Sativa (OTCMKTS:CBDS) researches and develops specialized natural cannabis-related products.Last August, CBDS stock found support around the $2 level. After rallying and then trending lower, it once again found support at this level at the end of April and throughout May.Then the level was broken, and the stock traded lower before recovering. Now $2 is a resistance level. How does this happen? How does a level that was formally support become a resistance level? * 5 Cheap Stocks to Buy Now That the Fed Cut Rates Consider the following. The people who bought the stock at $2 are losing money once it trades lower. They tell themselves that if the stock recovers and gets back to $2, they will sell it so they can get out break even. (Sound familiar?) This concentration of sellers is what creates a resistance level. Green Organic Dutchman Holdings (TGODF)Green Organic Dutchman Holdings (OTCMKTS:TGODF) provides medical cannabis solutions. The downtrend that began in TGODF stock in April seems to have broken.Some people do not understand how profitable the ability to draw and understand trendlines can be. It is obviously an art and not a science, but with some practice and an understanding it will help your trading or investing.In financial markets, prices are always doing one of three things -- going up, going down, or staying the same. If they are going up, the forces of demand are in control of the market. When prices are going lower, the forces of supply are in control. When prices are staying the same, the forces are equal. A popularly drawn trendline should simply be an illustration of these dynamics.We can see here that from a longer-term perspective, the forces of supply have been in control of this market. The downtrend line that I drew has been broken. This could mean that the forces of demand are about to take over and drive the price higher. CannTrust Holdings (CTST)CannTrust Holdings (NYSE:CTST) produces and sells medical cannabis.This company is now known affectionately as Can't Trust. This is because it has recently been accused of growing cannabis in illegal grow rooms that were not licensed. Since then CTST stock has dropped from $5 to $2.Senior management seems to have been well aware that this illicit activity was occurring. We know this because they discussed it in emails which are now in possession of the authorities. When will people ever learn? If you wouldn't want your grandmother to read it, do not put it in an email.My guess is that there are other companies that are engaged in similar illegal activity, and we will soon be hearing about others. * 10 Stocks to Buy on the Trade War Dip Over the past three weeks the stock has found support around the $2 level. Despite this, I can't trust CannTrust to be a safe investment. Until we know more details, I would stay away. CGrowth Capital (CGRA)CGrowth Capital (OTCMKTS:CGRA) is a holding company that is engaged in exploration, mining and commodities.This stock illustrates a valuable lesson. Every stock has a bid and an offer. The bid is the highest price someone will pay for a stock. The offer is the lowest price that someone is willing to sell it at.Now suppose a stocks bid is 1 cent and the offer is 2 cents. If someone sells it, the last trade will be 1 cent. Then suppose 10 minutes later someone else buys it. Now the last trade is 2 cents. The stock price has doubled but it hasn't really moved!CGRA stock illustrates a similar dynamic. Over the past week, the price has nearly doubled in value. It has gone from 45 thousandths to 70 thousandths of 1 cent. Could you have made money on this move? Absolutely not. Commission costs and market impact would have made it impossible. The stock has almost doubled in price but the shareholders haven't benefited.At the time of this writing Mark Putrino did not hold any positions in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk appeared first on InvestorPlace.

  • GlobeNewswire

    Emerald Health Therapeutics Outlines Production and Processing Advancements

    “With the first 1.1 million square foot (25 acre) greenhouse of our Pure Sunfarms joint venture now in full production and producing material net income and the second 1.1 million square foot greenhouse being converted for operation in 2020, we are now focused on finishing construction, licensing, and operational scaling of commercial cultivation and post-harvest processing in our other facilities and with third-party service providers, and have recently had multiple accomplishments to report,” said Riaz Bandali, Chief Executive Officer of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Appoints Chief Executive Officer

    OTCQX: EMHTF) has appointed Riaz Bandali as Chief Executive Officer. Mr. Bandali has over 25 years of experience in life sciences, with expertise in global operations, strategy development, innovation cultivation, M&A, and investment management spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

  • GlobeNewswire

    Emerald Health Therapeutics’ New Organic Cannabis Operation Receives Cultivation License for Outdoor Grow Area

    OTCQX: EMHTF) has received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, BC. The outdoor grow area is expected to be capable of producing approximately 10,000 kg of cannabis annually with multiple crops during a full growing season. With this license effective as of July 12, 2019, Emerald is positioned to deliver one harvest and a portion of the expected full production volume this year. The 12 acres (~500,000 square feet) of outdoor cultivation are part of an overall 20-acre site that includes 156,000 sq. ft. in two greenhouses.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Achieves Its Full Annualized Production Run-Rate

    OTCQX: EMHTF) 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has achieved its full production run-rate of 75,000 kilograms of dried cannabis at its 1.1 million square foot Delta 3 greenhouse in Delta, British Columbia. “Pure Sunfarms’ growing operation is setting the standard for large-scale low cost high quality cannabis production, which we believe serves as a strong indication of what the combined expertise of Emerald and Village Farms can accomplish,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Expands Distribution of its SYNC 25 CBD Oil to Two More Canadian Provinces

    VANCOUVER, British Columbia, July 10, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 9,960 40-ml units of its SYNC 25 CBD oil to.

  • GlobeNewswire

    Emerald Health Therapeutics Commends Government of Ontario for Expanding Retail Cannabis Store Licences in Canada’s Largest Province

    OTCQX: EMHTF) commends the Government of Ontario for its newly announced plans to expand the province’s brick-and-mortar retail sales network for adult-use cannabis. Emerald believes that this initiative will position the industry and the Company for significant sales growth in Canada’s largest province. “After the first 25 stores began to open in Ontario, the industry saw overall sales of cannabis basically double,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada

    OTCQX: EMHTF), through its joint venture Emerald Health Naturals (“EHN”), has introduced a cannabis-free herbal and botanical endocannabinoid-supporting health supplement product line in Canada. EHN’s Endo products, which do not contain cannabis or its derivatives, aim to support the endocannabinoid system to help maintain equilibrium in the body and are already available in over 200 natural health food stores across Canada.

  • GlobeNewswire

    Emerald Health Therapeutics Receives Cultivation License for New-Build Organic Cannabis Operation in British Columbia

    OTCQX: EMHTF) has received its initial cultivation license from Health Canada for its new organic cannabis growing facility in Metro Vancouver, BC. Tailor-made for Emerald to produce high-quality organic cannabis, the operation comprises two 78,000 square foot greenhouses and 12 acres (~500,000 square feet) of outdoor cultivation, with potential for an additional 12 acres.

  • GlobeNewswire

    Emerald Health Therapeutics Applauds the Government of Canada for the Release of Final Ingestible Regulations

    OTCQX: EMHTF) is pleased that today the Government of Canada released the final regulatory framework for ingestibles and edibles. “The clarity of the final regulatory framework provides is important for Emerald in bringing our new product categories such as vape pens, ingestibles and edibles to market,” said Allan Rewak, VP Communications and Stakeholder Relations. The regulatory framework announced by Health Canada prohibits product forms that could be appealing to children and youth, combine alcohol or nicotine with cannabis and restrict production of infused cannabis products to dedicated licenced cannabis facilities approved by Health Canada.

  • GlobeNewswire

    Emerald Health Therapeutics to Present At Oppenheimer Consumer Growth and E-Commerce Conference

    OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, will participate in the Oppenheimer 19th Annual Consumer Growth and E-Commerce Conference on June 18, 2019 in Boston, MA. Bernie Hertel, Vice President of Finance and Communications, Emerald Health Sciences, will present a corporate overview and be available for 1x1 meetings.

  • GlobeNewswire

    Emerald Health Therapeutics Contracts for 1,200 Acres of Canadian Hemp Harvest, Reports Significant Progress on Factors Group Extraction Facility, and Forms US Hemp Subsidiary

    OTCQX: EMHTF) reports that is has expanded its agreement to purchase harvested hemp flower and leaf, or hemp chaff, from Emerald Health Hemp Inc. (“EHH”) from 1,000 to 1,200 acres for 2019. EHH is a wholly owned subsidiary of Emerald Health Sciences Inc. and a related party of Emerald. Based on last year’s harvest, Emerald expects production from the 1,200 acres to be at least 270,000 kg of hemp chaff in 2019 with, conservatively, approximately 2% cannabidiol (“CBD”) content.

  • OTC Markets Group Launches OTCQX Cannabis Index
    PR Newswire

    OTC Markets Group Launches OTCQX Cannabis Index

    NEW YORK , June 4, 2019 /PRNewswire/ --  OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index ...

  • GlobeNewswire

    Emerald Health Therapeutics to Participate at Investment and Industry Conferences in June

    VANCOUVER, British Columbia, June 03, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in multiple upcoming investment and.

  • GlobeNewswire

    Emerald Health Therapeutics Reports First Quarter 2019 Financial Results; Demonstrates Continued Growth in Sales

    VANCOUVER, British Columbia, May 31, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended.


    Emerald Health Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 31, 2019 / Emerald Health Therapeutics, Inc. (TSXVENTURE: EMHTF ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 31, 2019 ...

  • GlobeNewswire

    Emerald Completes Issuance of Shares in Lieu of Cash Due for Verdélite Acquisition

    OTCQX: EMHTF) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have received 2,129,707 shares of Emerald (the "Shares") in lieu of $7.5 million of the $22.5 million they were to receive as the final payment for their shares of Verdélite. Each Share was valued at $3.5216, the five-day volume-weighted average price of the common shares of Emerald on the TSX Venture Exchange (the "TSXV"), discounted 10%, calculated as of April 30, 2019. The agreement to receive shares in lieu of cash was previously announced by the Company on May 1, 2019.

  • GlobeNewswire

    Emerald Health Therapeutics to Lead International Affairs Council on CBD and Hemp’s Dialog with FDA on CBD Product Policy as Part of the American Trade Association for Cannabis and Hemp

    OTCQX: EMHTF) has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US Food & Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade. The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the US.

  • GlobeNewswire

    Emerald Health Therapeutics Appoints Chief Operating Officer

    VICTORIA, British Columbia, May 22, 2019 -- Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has appointed Sean Rathbone as Chief Operating Officer. Mr..

  • GlobeNewswire

    Emerald Health Therapeutics to Hold Conference Call on First Quarter 2019 Financial Results on May 31st

    OTCQX: EMHTF) will host its first quarter 2019 financial results conference call on Friday, May 31st, 2019 at 10:30 a.m. ET. The Company will report its financial results for the first quarter ended March 31, 2019, after the market close on Thursday, May 30th, 2019. Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Pure Sunfarms’ Receipt of Standard Processing License for Delta 3 Greenhouse Facility

    OTCQX: EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received a Standard Processing License (the “Processing License”) from Health Canada for its 1.1 million square foot Delta 3 greenhouse facility. The Processing License permits Pure Sunfarms to extract and process cannabis at its Delta 3 facility, which will enable the development and manufacture of products derived from cannabis, including oils, other concentrates, and edibles. Pure Sunfarms will require an additional amendment to its sales license to sell cannabis oil, which it expects to be distributing to provincial/territorial distributors and private retailers by the fourth quarter of this year.

  • PR Newswire

    Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...